RESEARCH PEPTIDE FUNDAMENTALS / FAQ
Questions From the Research Record
Direct, citation-anchored answers to what people most often search about these five compounds.
What does BPC-157 do in the body?
In animal studies, BPC-157 promotes the growth of new blood vessels (angiogenesis) through the VEGFR2-Akt-eNOS pathway, which is the mechanism most consistently linked to its reported tissue-repair effects on tendons, ligaments and gut lining [4]. It has also been shown in rodents to accelerate healing of gastric ulcers and a fully transected Achilles tendon [5][6]. Human data are limited to a small IV safety pilot in two adults, which found no adverse effects but did not test whether it works [1].
Is BPC-157 a growth hormone?
No. BPC-157 is a 15-amino-acid pentadecapeptide derived from a gastric-juice protein, structurally unrelated to growth hormone or to growth-hormone-releasing hormone. Its reported tissue-repair effects are attributed mainly to angiogenesis and cytoprotection rather than to any growth-hormone pathway, though one proposed route involves sensitizing growth-hormone receptors in tendon fibroblasts specifically — a narrower, local effect, not a systemic GH increase.
Does BPC-157 work immediately?
There is no published human efficacy data establishing a timeline for BPC-157, immediate or otherwise — a 2025 review found only three small human pilot studies exist, none designed to measure onset of effect [2]. In animal studies, effects such as ulcer healing and tendon repair were measured over days to weeks, not immediately. Reports of fast-feeling changes circulating in research communities are anecdotal, not clinical evidence.
Does BPC-157 damage the liver?
The only published human safety data — an IV pilot in two healthy adults dosed up to 20 mg — found no measurable change in hepatic biomarkers [1]. That is reassuring but far too small a sample to rule out liver effects at scale or over time. A 2025 review of the literature notes that human safety data overall remain extremely limited and recommends treating BPC-157 as investigational [2].
What is semaglutide?
Semaglutide is a synthetic peptide that mimics GLP-1, a gut hormone the body releases after eating. It is FDA-approved for type 2 diabetes, chronic weight management, reducing cardiovascular events in people with established heart disease and obesity, and, since 2025, a form of fatty liver disease. It is given as a once-weekly injection or a once-daily oral tablet.
What is semaglutide used for?
FDA-approved uses include lowering blood glucose in type 2 diabetes, reducing body weight in chronic weight management, and reducing major cardiovascular events in adults with established cardiovascular disease and overweight or obesity [10]. In a landmark kidney-outcomes trial, it also reduced the risk of major kidney-disease events by 24% in people with type 2 diabetes and chronic kidney disease [9].
How does semaglutide work?
Semaglutide activates GLP-1 receptors throughout the body. At the pancreas, it boosts glucose-dependent insulin release and suppresses glucagon; in the gut, it slows how quickly the stomach empties; in the brain, it reaches appetite circuits in the hypothalamus and brainstem that regulate hunger and fullness. Its long, roughly week-long circulating half-life comes from a fatty side chain that binds to albumin in the blood, protecting it from rapid breakdown.
How does semaglutide work for weight loss?
The weight-loss effect is thought to be primarily central: semaglutide reaches hypothalamic and brainstem circuits that activate fullness signals and suppress hunger signals, reducing overall food intake and, according to research-community reports, the background preoccupation with food some call "food noise." In the STEP 1 trial, this produced a mean body-weight change of -14.9% at 68 weeks versus -2.4% with placebo [11].
What is thymosin alpha 1?
Thymosin alpha-1 (thymalfasin) is a 28-amino-acid immune-modulating peptide, cleaved from a larger precursor protein, that helps mature dendritic cells and coordinate the immune system's T-cell response. It is approved as a drug in more than 35 countries — mainly for chronic viral hepatitis — though it has never received US marketing approval [14].
What does thymosin alpha 1 do?
It signals through Toll-like receptors on dendritic cells and monocytes, driving their maturation and improving antigen presentation, which helps the immune system mount a more coordinated response. It also has a separate, counterbalancing regulatory arm that can generate regulatory T cells, which is why it is described as both immune-restoring and anti-inflammatory depending on context. Its largest recent trial, in sepsis, found no mortality benefit, showing this dual mechanism does not guarantee benefit in every acute-illness setting [13].
What is thymosin alpha 1 used for?
Internationally, thymalfasin is used mainly as an adjunct treatment for chronic viral hepatitis, and has been studied as an immune-support adjunct in certain cancers and infections [16]. A retrospective cohort of 76 patients with severe COVID-19 found it associated with significantly lower mortality, though this is observational evidence, not a randomized trial [15]. It is not approved for any indication in the United States.
Is thymosin alpha 1 FDA-approved?
No. Thymosin alpha-1, marketed abroad as thymalfasin, is approved in more than 35 other countries but has no US marketing approval [14]. In the US it is available only in investigational or compounding contexts, and its most rigorous recent trial — a 1,106-patient phase-3 sepsis study — found no significant mortality benefit [13].
What is CJC-1295?
CJC-1295 is a lab-modified, long-acting analog of growth-hormone-releasing hormone (GHRH). It comes in two forms: a long-acting "DAC" version that binds to a blood protein and lasts several days, with a measured half-life of 5.8 to 8.1 days, and a short-acting "no-DAC" version that lasts only minutes to hours [21]. Neither is approved for human use anywhere.
What does CJC-1295 do?
It binds the GHRH receptor on the pituitary gland, stimulating the release of growth hormone and, downstream, IGF-1. In a study of healthy adults, single doses produced 2- to 10-fold increases in plasma growth hormone lasting six days or more, with IGF-1 elevated for 9 to 11 days [21]. Research also shows the body's natural pulsatile pattern of GH release is preserved rather than flattened by continuous stimulation [22].
Is CJC-1295 safe?
It is not approved for human use anywhere, and published human evidence is limited to a small number of early pharmacology studies with no long-term safety data [21]. In 2024, FDA briefing materials for a pharmacy-compounding advisory committee cited immunogenicity and other safety concerns as part of the basis for not recommending it for compounding [18]. This site does not characterize CJC-1295 as either safe or unsafe for individual use — that determination requires a licensed clinician.
How much CJC-1295 should I take?
This site does not recommend a dose for any individual — that is not something a research digest can responsibly answer, and CJC-1295 is not an approved medicine with a labeled human dose. For context only: published human pharmacology studies tested single subcutaneous doses of 30 to 90 micrograms per kilogram in healthy adults under controlled research conditions, not as a treatment recommendation for self-administration [21][22].
What does the MOTS-c peptide do?
In cell and mouse studies, MOTS-c activates AMPK, a master metabolic switch, improving glucose uptake and insulin sensitivity, primarily in skeletal muscle [25]. A 2024 study found it also directly binds and activates an enzyme called casein kinase 2 in a tissue-specific way, which is linked to preventing muscle wasting and improving muscle glucose uptake in mice [23]. There is no published human trial testing whether administering MOTS-c to people produces these effects.
What are the negative side effects of MOTS-c?
There is no published human interventional trial data on MOTS-c, so no documented human side-effect profile exists to report. What the literature does establish are open safety questions: no measured human pharmacokinetics or dose-response, no FDA approval for any use, and unregulated research-chemical product quality that is not verified for purity or identity outside formal studies. Anecdotal reports of side effects circulating in research communities are not backed by controlled human data.
Is MOTS-c legal to buy?
MOTS-c is not approved by the FDA for any use and is sold only as a research chemical labeled not for human consumption. It is also treated as a prohibited substance in elite sport by anti-doping authorities. This site does not advise on the legality of purchasing or possessing MOTS-c in any jurisdiction; that depends on local law and is a question for legal counsel, not a research digest.
How often do you inject MOTS-c?
There is no established human dosing schedule for MOTS-c, because no human interventional trial testing administered doses has been published. Mouse studies cited in the literature used varying protocols to demonstrate exercise-mimetic effects on performance and metabolism [26], but rodent dosing schedules cannot be responsibly extrapolated to a human injection frequency, and this site does not recommend one.